Neil E. Reiner
Chief Tech/Sci/R&D Officer at Indel Therapeutics, Inc.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Mary Ackenhusen | F | - |
Vancouver Coastal Health Research Institute
Vancouver Coastal Health Research Institute Miscellaneous Commercial ServicesCommercial Services Vancouver Coastal Health Research Institute operates as a health research institute. It offers orientation, clinical trials administration, intellectual property, and community research services. The company is headquartered in Vancouver, Canada. | - |
Terry Sumner | M | - |
University of British Columbia
| - |
Roger Léger | M | - |
Indel Therapeutics, Inc.
Indel Therapeutics, Inc. BiotechnologyHealth Technology Indel Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of antibiotics to address the health crisis caused by antibiotics resistance. The firm’s programs are based on Indel's paradigm-changing antimicrobial drug discovery platform that has opened drug targets for the treatment of bacterial and parasitic infections, and potentially, fungal and viral infections. The company was founded by Malcolm C. Kendall in 2008 and is headquartered in Vancouver, Canada.^ ^ | - |
Kevin McElwee | M | 54 |
Vancouver Coastal Health Research Institute
Vancouver Coastal Health Research Institute Miscellaneous Commercial ServicesCommercial Services Vancouver Coastal Health Research Institute operates as a health research institute. It offers orientation, clinical trials administration, intellectual property, and community research services. The company is headquartered in Vancouver, Canada.
University of British Columbia
| 20 years |
Richard J. White | M | 82 |
Indel Therapeutics, Inc.
Indel Therapeutics, Inc. BiotechnologyHealth Technology Indel Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of antibiotics to address the health crisis caused by antibiotics resistance. The firm’s programs are based on Indel's paradigm-changing antimicrobial drug discovery platform that has opened drug targets for the treatment of bacterial and parasitic infections, and potentially, fungal and viral infections. The company was founded by Malcolm C. Kendall in 2008 and is headquartered in Vancouver, Canada.^ ^ | - |
Jason Hein | M | 45 |
University of British Columbia
| 9 years |
Mads Daugaard | M | - |
University of British Columbia
| - |
Gary Bull | M | - |
University of British Columbia
| - |
Scott Dunbar | M | - |
University of British Columbia
| 10 years |
Evan Wood | M | - |
University of British Columbia
| - |
Alan Mackworth | M | - |
University of British Columbia
| - |
Caroline MacCallum | M | - |
University of British Columbia
| - |
Peter Latta | M | - |
University of British Columbia
| - |
Steven Plotkin | M | - |
University of British Columbia
| 23 years |
Shervin Teymouri | M | 42 |
University of British Columbia
| - |
Marianne D. Sadar | M | 61 |
University of British Columbia
| - |
Dalton Larson | M | 84 |
University of British Columbia
| - |
Alan Rabinowitz | M | - |
University of British Columbia
| - |
Manon Harvey | F | - |
University of British Columbia
| 5 years |
John Shepherd | M | - |
University of British Columbia
| - |
Brian K. Kwon | M | - |
University of British Columbia
| - |
Maryse Bélanger | F | 62 |
University of British Columbia
| - |
Shahram Tafazoli | M | - |
University of British Columbia
| - |
Allan Collings | M | - |
Indel Therapeutics, Inc.
Indel Therapeutics, Inc. BiotechnologyHealth Technology Indel Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of antibiotics to address the health crisis caused by antibiotics resistance. The firm’s programs are based on Indel's paradigm-changing antimicrobial drug discovery platform that has opened drug targets for the treatment of bacterial and parasitic infections, and potentially, fungal and viral infections. The company was founded by Malcolm C. Kendall in 2008 and is headquartered in Vancouver, Canada.^ ^ | 13 years |
Nancy Mckenzie | F | - |
University of British Columbia
| - |
Irwin Kuntz | M | - |
Indel Therapeutics, Inc.
Indel Therapeutics, Inc. BiotechnologyHealth Technology Indel Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of antibiotics to address the health crisis caused by antibiotics resistance. The firm’s programs are based on Indel's paradigm-changing antimicrobial drug discovery platform that has opened drug targets for the treatment of bacterial and parasitic infections, and potentially, fungal and viral infections. The company was founded by Malcolm C. Kendall in 2008 and is headquartered in Vancouver, Canada.^ ^ | - |
Bern Klein | M | 65 |
University of British Columbia
| - |
Deb Zehr | F | - |
University of British Columbia
| - |
Rob Scott | M | - |
University of British Columbia
| - |
Allan Moss | M | - |
University of British Columbia
| - |
Natasha Affolder | F | - |
University of British Columbia
| - |
Ed Putnins | M | - |
University of British Columbia
| - |
Matthew Evenden | M | - |
University of British Columbia
| - |
Sally Aitken | F | - |
University of British Columbia
| - |
Debbie Harvie | F | - |
University of British Columbia
| - |
Brian Heathcote | M | - |
University of British Columbia
| - |
Janet Teasdale | F | - |
University of British Columbia
| - |
Susan Danard | F | - |
University of British Columbia
| - |
Darrin Lehman | M | - |
University of British Columbia
| - |
Adriaan de Jager | M | - |
University of British Columbia
| - |
Kathleen Leahy | F | - |
University of British Columbia
| - |
John Metras | M | - |
University of British Columbia
| - |
Karyn Magnusson | F | - |
University of British Columbia
| - |
Trish Pekeles | F | - |
University of British Columbia
| - |
Allison Matacheskie | F | - |
University of British Columbia
| - |
Billy Jong | M | - |
University of British Columbia
| - |
Julie Ovenell | F | - |
University of British Columbia
| - |
Julie Wagemakers | F | - |
University of British Columbia
| - |
Tracey Carmichael | F | - |
University of British Columbia
| - |
Mathias Schütz | M | - |
University of British Columbia
| 13 years |
Philippe Margaron | M | - |
University of British Columbia
| - |
David Sidoo | M | 64 |
University of British Columbia
| 10 years |
Terrance P. Snutch | M | - |
University of British Columbia
| - |
Mike Harcourt | M | - |
University of British Columbia
| - |
David Dreisinger | M | 65 |
University of British Columbia
| 40 years |
Stephen Charles Anderson | M | 61 |
University of British Columbia
| - |
Wang-Chan Wong | M | 69 |
University of British Columbia
| - |
Douglas Beder | M | 83 |
University of British Columbia
| - |
Neil Cashman | M | 72 |
University of British Columbia
| 19 years |
Arc Rajtar | M | - |
University of British Columbia
| - |
Thomas J. Kinahan | M | - |
University of British Columbia
| - |
Tony David | M | 83 |
University of British Columbia
| - |
Anthony G. Phillips | M | - |
University of British Columbia
| - |
Andrew J. Rae | M | - |
University of British Columbia
| - |
Choi Kay Wong | F | 58 |
University of British Columbia
| - |
Lee Groat | M | - |
University of British Columbia
| 21 years |
Maureen Howe | M | 66 |
University of British Columbia
| - |
George Wesley Poling | M | 89 |
University of British Columbia
| 56 years |
Michael J. A. Walker | M | - |
University of British Columbia
| - |
Randall Findlay | M | 73 |
University of British Columbia
| - |
Douglas Harding Mitchell | M | 85 |
University of British Columbia
| 14 years |
Michael Jeffrey Abrams | M | 68 |
University of British Columbia
| - |
Patrick Scannon | M | 76 |
Indel Therapeutics, Inc.
Indel Therapeutics, Inc. BiotechnologyHealth Technology Indel Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of antibiotics to address the health crisis caused by antibiotics resistance. The firm’s programs are based on Indel's paradigm-changing antimicrobial drug discovery platform that has opened drug targets for the treatment of bacterial and parasitic infections, and potentially, fungal and viral infections. The company was founded by Malcolm C. Kendall in 2008 and is headquartered in Vancouver, Canada.^ ^ | - |
Vanessa Avila | F | 47 |
University of British Columbia
| - |
William G. Dunford | M | - |
University of British Columbia
| - |
Iain Cleator | M | - |
University of British Columbia
| - |
Robert Snukal | M | - |
University of British Columbia
| - |
Joel Solomon | M | - |
University of British Columbia
| 6 years |
Elisabeth Maurer-Spurej | M | - |
University of British Columbia
| - |
Douglas Bunker | M | - |
University of British Columbia
| - |
Donald Richard Ricci | M | 76 |
University of British Columbia
| - |
Marcello M. Veiga | M | - |
University of British Columbia
| - |
Stephen Lam | M | - |
University of British Columbia
| - |
Barton Finlay | M | - |
University of British Columbia
| - |
Maziar Badii | M | 54 |
University of British Columbia
| - |
Kamran Shojania | M | 60 |
University of British Columbia
| - |
Lana Eagle | F | - |
University of British Columbia
| - |
Martha Salcudean | M | - |
University of British Columbia
| - |
Poul Sorensen | M | - |
University of British Columbia
| - |
Don Mavinic | M | - |
University of British Columbia
| 41 years |
Keith R. Walley | M | - |
University of British Columbia
| - |
James Russell | M | - |
University of British Columbia
| - |
J. Basil Peters | M | - |
University of British Columbia
| - |
Yossef Av-Gay | M | 62 |
University of British Columbia
| 30 years |
Robert Cousland | M | - |
University of British Columbia
| - |
Dermot Kelleher | M | 68 |
University of British Columbia
| - |
Lindsay Machan | M | - |
University of British Columbia
| - |
Michael Tippett | M | - |
University of British Columbia
| - |
Raymond J. Andersen | M | 76 |
University of British Columbia
| 47 years |
Weiwei Jiang | M | 33 |
University of British Columbia
| 1 years |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
Canada | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Neil E. Reiner
- Personal Network